Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia ® (denosumab), to treat a variety of ...

What Are The Main Causes of An Overbite, And How Can It Be Treated?

Explore the causes and long-term health risks associated with overbite teeth, and discover treatment options for skeletal ...
Investopedia

Upper Middle and Lower Income Brackets Defined: How Much Income Counts for Each Category

Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Getty Images The median U.S. household ...